185 related articles for article (PubMed ID: 36958727)
21. Antidepressants for agitation and psychosis in dementia.
Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
[TBL] [Abstract][Full Text] [Related]
23. Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
Nirogi R; Jayarajan P; Benade V; Shinde A; Goyal VK; Jetta S; Ravula J; Abraham R; Grandhi VR; Subramanian R; Pandey SK; Badange RK; Mohammed AR; Jasti V; Ballard C; Cummings J
Int J Geriatr Psychiatry; 2022 Oct; 37(10):. PubMed ID: 36168659
[TBL] [Abstract][Full Text] [Related]
24. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
[TBL] [Abstract][Full Text] [Related]
25. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
Omerovic M; Hampel H; Teipel SJ; Buerger K
World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
[TBL] [Abstract][Full Text] [Related]
27. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
[TBL] [Abstract][Full Text] [Related]
28. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
[No Abstract] [Full Text] [Related]
29. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
30. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Aga VM
Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
[TBL] [Abstract][Full Text] [Related]
31. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
32. Role of citalopram in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Keltz MA; Smith JS
Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
[TBL] [Abstract][Full Text] [Related]
33. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
34. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
[TBL] [Abstract][Full Text] [Related]
35. Investigational drugs for treating agitation in persons with dementia.
Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
[TBL] [Abstract][Full Text] [Related]
36. Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.
McClam TD; Marano CM; Rosenberg PB; Lyketsos CG
Harv Rev Psychiatry; 2015; 23(5):377-93. PubMed ID: 26332220
[TBL] [Abstract][Full Text] [Related]
37. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
[TBL] [Abstract][Full Text] [Related]
38. Management of neuropsychiatric symptoms in dementia.
Devanand DP
Curr Opin Neurol; 2023 Oct; 36(5):498-503. PubMed ID: 37639488
[TBL] [Abstract][Full Text] [Related]
39. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
[TBL] [Abstract][Full Text] [Related]
40. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
